Stockreport

Sonnet BioTherapeutics Announces Exercise of Warrants for $3.4 Million in Gross Proceeds

Sonnet BioTherapeutics Holdings, Inc.  (SONN) 
PDF PRINCETON, N.J., June 20, 2024 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) (the “Company” or “Sonnet”), a clinical-stage company developing [Read more]